Core Viewpoint - Lai Kai Pharmaceutical-B (02105) has seen a significant stock increase of over 36% in the last three trading days, driven by positive initial results from its LAE102 drug for obesity treatment in China [1] Group 1: Stock Performance - Lai Kai Pharmaceutical-B's stock rose by 6.11% to HKD 17.55, with a trading volume of HKD 118 million [1] - The stock has experienced a cumulative increase of 36% over the past three trading days [1] Group 2: Clinical Trial Results - The Phase I multi-dose escalation study (MAD study) for LAE102 has shown promising initial results, indicating a trend of muscle gain and fat loss [1] - In the 5th week, participants in the 6mg/kg dose group showed an average lean body mass increase of 1.7% and a fat mass reduction of 2.2% [1] - After adjusting for the placebo group, the average lean body mass increase reached 4.6%, while fat mass decreased by 3.6% [1] Group 3: Competitive Landscape - Eli Lilly's recent decision to halt the bimagrumab combination trial is seen as reducing potential competition for LAE102 [1] - The collaboration between Lai Kai and Eli Lilly highlights the value of the LAE102 pipeline, especially in light of the competitive advantages revealed in recent clinical trial data [1] Group 4: Analyst Ratings - DBS has reiterated a "Buy" rating for Lai Kai Pharmaceutical, citing significantly increased potential for the LAE102 drug to prevent muscle loss [1] - The clinical trial information released by Eli Lilly in late September suggests that LAE102's competitive advantages may be more pronounced than previously expected [1] - The Phase I clinical trial for LAE102 is expected to conclude in September, with subsequent data releases likely to attract interest from Eli Lilly and other international pharmaceutical companies for licensing agreements [1]
港股异动 | 来凯医药-B(02105)再涨超6% 近三个交易日累计涨36% LAE102 I期临床MAD研究初步结果积极